Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Neurological conditions

Cannabis-derived medicine for treatment of two rare forms of epilepsy approved by EMA committee

Epidyolex has been recommended for marketing authoristation by the European Medicines Agency’s Committee for Medicinal Products for Human Use.

A European Medicines Agency (EMA) committee has approved in principle what could be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsy.

The European Commission will now make a final decision on the marketing authorisation application for Epidyolex (GW Pharmaceuticals), expected by September 2019.

The EMA’s Committee for Medicinal Products for Human Use has granted a positive opinion for Epidyolex (cannabidiol [CBD] oral solution) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS).

The CBD oral solution has been recommended as an adjunctive therapy for use in conjunction with clobazam for patients aged two years and older.

“This is a significant milestone for patients with LGS and DS, as there remains a severe unmet medical need for these rare, lifelong forms of epilepsy,” said Martin Brodie, president of the International Bureau for Epilepsy.

“Today’s positive opinion brings hope, to both patients and their families, of a treatment option which has the potential to better control seizures and notably improve quality of life.”

The positive opinion was based on the results of four randomised controlled phase III trials comprising more than 714 patients with either LGS or DS.

Currently, the only cannabis-based medical product licensed by the Medicines and Healthcare product Regulatory Agency is nabiximols (Sativex; GW Pharmaceuticals) for the treatment of multiple sclerosis.

The US Food and Drug Administration approved GW’s cannabidiol oral solution in June 2018 under the trade name Epidiolex for the treatment of seizures associated with LGS or DS in patients two years of age or older.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206869

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Statistics

    Pharmaceutical Statistics

    This book on basic statistics has been specifically written for pharmacy students.

    £33.00Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.